Genetically modifying T-cells cuts blood cancer progression by 74%, trial finds

A revolutionary blood cancer treatment that genetically modifies patient cells to fight the disease cuts the risk of it progressing by 74%, a world-first clinical trial has found.

Ciltacabtagene autoleucel, also known as Carvykti, belongs to a class of drugs known as Car-T therapies. They work by weaponising a patient’s own disease-fighting T-cells, genetically engineering them to target specific proteins on cancer cells, and replacing them to seek out and attack cancer. “Ciltacabtagene autoleucel has not only shown that it delivers remarkably effective outcomes compared to patients’ current options, but also that it can be used safely earlier in the treatment phase.”The groundbreaking treatment works by removing some T-cells from a patient’s blood, which are then modified in a laboratory, so they have specific proteins called receptors. The receptors allow the modified T-cells to recognise the cancer cells.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Disgraced war veteran may have committed criminal offence, judge findsWar veteran Ben Roberts-Smith may have committed a criminal offence by sending threatening letters to a former SAS colleague, a Federal Court judge finds.
Source: abcnews - 🏆 5. / 83 Read more »